RSS
Biofarm had a net profit increase of 22%, 36.4 million lei for Q1
Biofarm, one of the biggest producers of drugs and food supplements in Romania, had an increase of the net profit of 22%, 36.4 million lei, while the net income from sales achieved in the first part of the year increased by 14%, 117.98 million lei.
In Q1, the share of export sales was approximately 2.1% of the total net sales of Biofarm. The company products were exported to five countries: the Republic of Moldova, Hungary, Russia, Ukraine and Azerbaijan.
For 2021, Biofarm SA proposes to increase the market share, to increase the efficiency of the operational activity and to consolidate the competitive advantage of the products portfolio, with a view to increasing the profit quota.
As such, the pharma market has a positive evolution, described as increasing competition, massive investment in the media and the existence on the market of international producers of OTC and food supplements.
Biofarm was set up in 1990 and it is one of the biggest producers of drugs and food supplements in Romania. It is the biggest Romanian producer of soft capsules, among the first three Romanian producers of solutions and suspensions for oral administration and one of the biggest producers of pills in Romania.
The company has over 200 products in its portfolio and covers over 60 therapy areas. For nine out of the 60 therapy areas, Biofarm is the market leader.
Biofarm has a capitalisation of 605 million lei. SIF Muntenia owns 51.57% of the shares, and SIF Banat Crisana 36.74%.